The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
|
Activity Number:
|
89
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Sunday, July 31, 2011 : 4:00 PM to 5:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #302536 |
|
Title:
|
Analysis of a Composite Endpoint Under Different Censoring Schemes for Component Events
|
|
Author(s):
|
Chunlei Ke*+ and Beiying Ding and Jianming Wang and Qi Jiang
|
|
Companies:
|
Amgen Inc. and Amgen Inc. and Novartis Oncology and Amgen Inc.
|
|
Address:
|
One Amgen Drive, Thousand Oaks, CA, 91320,
|
|
Keywords:
|
Composite endpoint ;
censoring ;
Kaplan Merier estiatme
|
|
Abstract:
|
Composite Endpoints are common in clinical trials, especially in the context of survival analysis. Time to a composite endpoint is defined as time from randomization to the first occurrence of any of the component events. Different component events may have different censoring mechanisms, which may lead to different censoring times. Usually some ad-hoc methods, eg, using the longest censoring time, are chosen for simplicity. These conventional approaches, however, may lead to biased or inconsistent estimate of survival function and treatment effect. We first propose a generalized Kaplan-Meier estimate of the survival function for the composite endpoint under certain conditions. A Greenwood-type asymptotic variance estimate is derived. We then extend the log-rank test to make comparisons of the survival functions. Some simulations and applications to real data are also presented.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.